

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	ation			
1. Given Name (First Name) Lizza	2. Surname (Last Nar Hendriks	ne)		3. Date 18-March-2020
4. Are you the corresponding author?	✓ Yes No			
5. Manuscript Title First-line immune-chemotherapy combi	nation for squamous	S NSCLC is already	a reality	
6. Manuscript Identifying Number (if you known TLCR-20-345	ow it)			
Section 2. The Work Under Co	onsideration for P	ublication		
Did you or your institution at any time receivany aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to gran			
Section 3. Relevant financial a	activities outside	the submitted v	vork.	
Place a check in the appropriate boxes in of compensation) with entities as descril clicking the "Add +" box. You should rep	bed in the instruction	ns. Use one line for	r each entit	ty; add as many lines as you need by
Are there any relevant conflicts of intere	st? ✓ Yes	No		
If yes, please fill out the appropriate info	rmation below.			
Name of Entity	Grant? Personal Fees?	Non-Financial Support?	Other?	Comments
ooehringer ingelheim			√ fe	es for institution for advisory board
BMS			✓ fe	es for institution for advisory board
Roche				avel support (self), ad board nstitution)
BMS			√ tra	avel support (self)
Roche			re	esearch funding (institution)
Boehringer Ingelheim	✓		re	esearch funding (institution)



Name of Entity	Grant?	Personal Fees	Non-Financial Support?	Other?	Comments
Astra Zeneca				✓	mentorship program with key opinion leaders: funded by AstraZeneca
Quadia		\checkmark			educational webinars
Astra Zeneca	✓				research funding (institution)
Lilly				✓	ad board (institution)
Roche				✓	ad board (institution)
Pfizer				✓	ad board (institution)
MSD				✓	speaker (institution), ad board (institution)
Takeda					ad board (institution)
Do you have any patents, whether plann Section 5. Relationships note.	ed, pend	ing or issue		nt to the	work? Yes 🗸 No
Relationships not c	overed	above			
Are there other relationships or activities potentially influencing, what you wrote i				influence	d, or that give the appearance of
Yes, the following relationships/cond					
At the time of manuscript acceptance, jo On occasion, journals may ask authors to	urnals wi	ll ask autho	ors to confirm and	d, if neces	sary, update their disclosure statements

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Hendriks reports other from boehringer ingelheim, other from BMS, other from Roche, other from BMS, grants from Roche, grants from Boehringer Ingelheim, other from AstraZeneca, personal fees from Quadia, grants from Astra Zeneca, other from Lilly, other from Roche, other from Pfizer, other from MSD, from Takeda, outside the submitted work;

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Menis 1



Identifying Information

Section 1.

ICMJE Form for Disclosure of Potential Conflicts of Interest

Given Name (First Name) Jessica	2. Surname (L Menis	ast Name)			3. Date 17-March-2020	
4. Are you the corresponding author?	Yes	∕ No	Correspond	ling Author's	s Name	
5. Manuscript Title First-line immune-chemotherapy comb	ination for squ	iamous NSC	LC is already	a reality		
6. Manuscript Identifying Number (if you kn TLCR-20-345	ow it)					
Section 2. The Work Under Co	onsideration	for Public	ation			
Did you or your institution at any time recei any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited					r
Section 3. Relevant financial	activities ou	tside the s	ubmitted s	work		
Place a check in the appropriate boxes in of compensation) with entities as descri clicking the "Add +" box. You should rep Are there any relevant conflicts of intere If yes, please fill out the appropriate info	bed in the instoort relationshort? Yes	ructions. Us ips that wer	se one line fo	r each enti	ty; add as many lines as you need by	
N	Grant? Per	sonal Nor				
Name of Entity		3	n-Financial upport <mark>?</mark>	Other?	Comments	
Name of Entity Boehringer-Ingelheim,	F			a₀ ✓ re	Comments dvisory, speaker, travel/conference elimbursement, fees for educational ebinar	
	Fo	ees? S		a a re	dvisory, speaker, travel/conference eimbursement, fees for educational	
Boehringer-Ingelheim,	F	ees? S		✓ re w	dvisory, speaker, travel/conference eimbursement, fees for educational rebinar dvisory, speaker, travel/conference	
Boehringer-Ingelheim, MSD	✓ F	ees? S		are w	dvisory, speaker, travel/conference eimbursement, fees for educational rebinar dvisory, speaker, travel/conference eimbursement dvisory, speaker, travel/conference	
Boehringer-Ingelheim, MSD Roche	V V	ees? S		are www.	dvisory, speaker, travel/conference eimbursement, fees for educational ebinar dvisory, speaker, travel/conference eimbursement dvisory, speaker, travel/conference eimbursement	

Menis 2



Section 4. Intellectual Property Patents & Copyrights					
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo					
Section 5. Relationships not covered above					
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?					
Yes, the following relationships/conditions/circumstances are present (explain below):					
✓ No other relationships/conditions/circumstances that present a potential conflict of interest					
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.					
Section 6. Disclosure Statement					
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.					
Dr. Menis reports grants, personal fees and other from Boehringer-Ingelheim,, grants and other from MSD, grants and other from Roche, grants and other from Astrazeneca, grants and other from Ipsen, grants and other from BMS, outside the submitted work; .					

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Menis 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

REMON 1



Section 1. Identifying I				
Identifying I	nformation			
1. Given Name (First Name) JORDI	2. Surname (Last Name REMON	2)	3. Date 17-March-2020	_
4. Are you the corresponding author	r? Yes ✓ No	Corresponding Author Lizza Hendriks	's Name	
5. Manuscript Title First-line immune-chemotherapy	combination for squamous N	NSCLC is already a reality		
6. Manuscript Identifying Number (if TLCR-20-345	f you know it)			
Section 2. The Work Un	der Consideration for Pul	blication		
any aspect of the submitted work (in statistical analysis, etc.)? Are there any relevant conflicts or	cluding but not limited to grants	s, data monitoring board, stud	nt, commercial, private foundation, etc.) f dy design, manuscript preparation,	for
Relevant fina	ncial activities outside th	ne submitted work.		
	described in the instructions uld report relationships that were the second relationships the second relationships that were the second relationships the second relationships that were the second relationships that were the second relationships the second	. Use one line for each ent were present during the	al relationships (regardless of amoun ity; add as many lines as you need by 36 months prior to publication .	
If yes, please fill out the appropria	ate information below.			
Name of Entity	Grant? Personal I	Non-Financial Support?	Comments	
OSE PHARMA			TRAVEL / ACOMMODATION	
ASTRA ZENECA			ADVISORY	
MSD			TRAVEL 7 ADVISORY	
PFIZER			ADVISORY	
ROCHE			FRAVEL	

REMON 2



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. REMON reports other from OSE PHARMA, other from ASTRA ZENECA, other from MSD, other from PFIZER, other from ROCHE, outside the submitted work; .

Evaluation and Feedback

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$

REMON 3